Supplier
Ephraim Mcdowell Regional Medical Center Incorporated
Ephraim Mcdowell Regional Medical Center Incorporated was paid $59.95M by Medicaid between Jan 2018 and Dec 2024, across 338 billing codes. Its largest line is 74177, Computed tomography, abdomen and pelvis; with contrast material — 10% of everything it billed.
33Billing provider infoEPHRAIM MCDOWELL REGIONAL MEDICAL CENTER INCORPORATED
DANVILLE, KY 40422
DANVILLE, KY 40422
33aNPI1821135963assigned 01/30/2007
33bProvider typePharmacy
28Total paid$59.95M
24GClaims1,036,528
24DCodes billed338
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pharmacy providers in Kentucky
Rank by total paid#1 of 54
Median peer was paid$84.85
This provider vs. median706,588×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SNAPP, WILLIAM controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 144,871 | $8.19M | |
| 2019 | 136,996 | $7.99M | |
| 2020 | 131,799 | $6.81M | |
| 2021 | 152,201 | $8.39M | |
| 2022 | 165,971 | $8.98M | |
| 2023 | 171,312 | $10.49M | |
| 2024incomplete | 133,378 | $9.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 10% | 7,785 | 5,869 | $6.27M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.1% | 20,735 | 16,021 | $3.67M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.2% | 21,890 | 18,727 | $3.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.4% | 26,153 | 22,856 | $2.66M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.9% | 4,612 | 3,979 | $2.34M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.1% | 22,994 | 7,933 | $1.89M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.0% | 19,251 | 7,001 | $1.77M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 5,914 | 4,580 | $1.54M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.5% | 4,180 | 3,849 | $1.49M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.5% | 2,609 | 1,872 | $1.48M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.3% | 15,536 | 5,693 | $1.37M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.1% | 3,221 | 1,668 | $1.29M |
326 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 12,396 | $1.10M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 15,059 | $1.07M |
| G0378 | Hospital observation service, per hour | 1.6% | 9,006 | $938K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 2,337 | $928K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 16,662 | $787K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 2,925 | $768K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 17,543 | $676K |
| 47563 | 1.1% | 442 | $672K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 3,218 | $652K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 4,492 | $644K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 16,006 | $632K |
| 80053 | Comprehensive metabolic panel | 1.0% | 72,475 | $628K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,622 | $591K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,394 | $583K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 10,928 | $579K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,242 | $570K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,358 | $563K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,697 | $553K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 454 | $538K |
| 93017 | <1% | 2,190 | $512K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 15,052 | $450K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,728 | $443K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,244 | $427K |
| 87631 | <1% | 3,916 | $427K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 57,368 | $405K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,639 | $400K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 323 | $393K |
| 71250 | <1% | 1,361 | $389K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 13,710 | $378K |
| 36415 | Collection of venous blood by venipuncture | <1% | 91,183 | $345K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 586 | $331K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 370 | $318K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,367 | $317K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,317 | $314K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,529 | $303K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 895 | $298K |
| 92526 | <1% | 3,191 | $293K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,325 | $290K |
| 76830 | Ultrasound, transvaginal | <1% | 1,237 | $269K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 285 | $250K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,121 | $244K |
| 87486 | <1% | 8,447 | $238K | |
| 76642 | <1% | 2,246 | $234K | |
| 87581 | <1% | 8,193 | $232K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,253 | $196K |
| 87507 | <1% | 579 | $193K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,419 | $178K |
| 78227 | <1% | 439 | $176K | |
| 84484 | <1% | 13,443 | $175K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 753 | $171K |
| 96376 | <1% | 4,774 | $168K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,542 | $163K |
| 97162 | <1% | 2,882 | $162K | |
| 97113 | <1% | 1,844 | $160K | |
| 73630 | <1% | 2,384 | $153K | |
| 59025 | Fetal non-stress test | <1% | 3,902 | $142K |
| 70486 | <1% | 510 | $139K | |
| 72141 | <1% | 378 | $139K | |
| 73560 | <1% | 2,231 | $135K | |
| 73610 | <1% | 1,863 | $130K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,018 | $126K |
| 88304 | <1% | 2,945 | $120K | |
| 93971 | <1% | 1,198 | $116K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 503 | $113K |
| 83880 | <1% | 3,874 | $113K | |
| 70498 | <1% | 334 | $111K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,655 | $105K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,002 | $100K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,453 | $100K |
| 73130 | <1% | 1,463 | $98K | |
| 96415 | <1% | 373 | $95K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,810 | $91K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,834 | $91K |
| 73030 | <1% | 1,367 | $89K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,388 | $89K |
| 74018 | <1% | 1,607 | $87K | |
| 83690 | <1% | 9,346 | $85K | |
| 84703 | <1% | 10,674 | $85K | |
| 97166 | <1% | 1,369 | $85K | |
| 80061 | Lipid panel | <1% | 7,121 | $84K |
| 62323 | <1% | 225 | $84K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 24,479 | $84K |
| 97161 | <1% | 1,211 | $83K | |
| 96367 | <1% | 2,870 | $82K | |
| 70496 | <1% | 196 | $82K | |
| 83605 | <1% | 7,150 | $82K | |
| 94060 | <1% | 361 | $80K | |
| 76536 | <1% | 575 | $79K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,033 | $78K |
| 81001 | <1% | 21,109 | $76K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,415 | $76K |
| 36591 | <1% | 3,571 | $74K | |
| 77065 | Tomosynthesis, mammo | <1% | 915 | $71K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,898 | $69K |
| 83735 | <1% | 10,568 | $69K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,764 | $67K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,351 | $67K |
| 84145 | <1% | 3,172 | $65K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 160 | $62K |
| 93226 | <1% | 268 | $59K | |
| 97116 | <1% | 723 | $58K | |
| 82728 | <1% | 4,951 | $56K | |
| 73110 | <1% | 775 | $55K | |
| 93970 | <1% | 273 | $54K | |
| 95811 | <1% | 73 | $52K | |
| 84439 | <1% | 5,762 | $50K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,086 | $50K |
| 82607 | <1% | 3,918 | $49K | |
| 85027 | <1% | 8,221 | $49K | |
| 94760 | <1% | 3,756 | $49K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,017 | $48K |
| J3490 | Unclassified drugs | <1% | 4,938 | $46K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 462 | $46K |
| 80320 | <1% | 1,671 | $45K | |
| 77066 | Tomosynthesis, mammo | <1% | 426 | $45K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 911 | $45K |
| 96417 | <1% | 538 | $45K | |
| 80074 | <1% | 1,196 | $45K | |
| 88312 | <1% | 951 | $44K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,257 | $43K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,404 | $43K |
| 74300 | <1% | 296 | $42K | |
| 96368 | <1% | 1,949 | $42K | |
| 84702 | <1% | 3,031 | $40K | |
| 87077 | <1% | 6,803 | $40K | |
| 62369 | <1% | 343 | $40K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 145 | $40K |
| 62370 | <1% | 280 | $39K | |
| 74178 | <1% | 43 | $39K | |
| 12001 | <1% | 326 | $39K | |
| 87186 | <1% | 4,559 | $37K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 920 | $35K |
| 76770 | <1% | 186 | $35K | |
| 92610 | <1% | 235 | $34K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,355 | $34K |
| 85610 | <1% | 8,614 | $33K | |
| 94726 | <1% | 175 | $33K | |
| 72100 | <1% | 482 | $33K | |
| 93924 | <1% | 189 | $32K | |
| 87070 | <1% | 4,004 | $31K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,479 | $31K |
| 83550 | <1% | 4,169 | $31K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 262 | $30K |
| 86850 | <1% | 3,201 | $30K | |
| 84238 | <1% | 1,027 | $29K | |
| 87040 | <1% | 2,345 | $29K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 305 | $28K |
| 71271 | <1% | 775 | $28K | |
| 86140 | <1% | 4,589 | $27K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 382 | $27K |
| 83540 | <1% | 4,609 | $26K | |
| 82378 | <1% | 1,698 | $26K | |
| 85379 | <1% | 2,855 | $26K | |
| 84481 | <1% | 1,298 | $26K | |
| 82803 | <1% | 1,213 | $24K | |
| 47562 | <1% | 13 | $24K | |
| 93225 | <1% | 304 | $23K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 23 | $22K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 184 | $22K |
| 87150 | <1% | 512 | $22K | |
| 82962 | <1% | 6,430 | $21K | |
| 82746 | <1% | 1,784 | $21K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 573 | $20K |
| 85730 | <1% | 3,617 | $20K | |
| 44970 | <1% | 22 | $19K | |
| 73502 | <1% | 279 | $19K | |
| 86300 | <1% | 1,038 | $18K | |
| 95806 | <1% | 225 | $18K | |
| 72110 | <1% | 162 | $18K | |
| 88307 | <1% | 247 | $18K | |
| 73590 | <1% | 250 | $17K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,820 | $17K |
| 90715 | <1% | 822 | $16K | |
| 84112 | <1% | 199 | $16K | |
| 92523 | <1% | 148 | $16K | |
| 80329 | <1% | 226 | $15K | |
| C1781 | Mesh (implantable) | <1% | 48 | $15K |
| 77080 | <1% | 263 | $15K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 264 | $15K |
| 88300 | <1% | 1,068 | $14K | |
| 87503 | <1% | 633 | $14K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,286 | $13K |
| 83615 | <1% | 1,568 | $12K | |
| 84153 | <1% | 723 | $12K | |
| 82565 | <1% | 1,200 | $12K | |
| 82784 | <1% | 1,253 | $11K | |
| 73090 | <1% | 160 | $11K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 450 | $11K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,326 | $10K |
| 82550 | <1% | 1,585 | $10K | |
| 82077 | <1% | 477 | $10K | |
| 86901 | <1% | 3,258 | $10K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 39 | $10K |
| 86038 | <1% | 955 | $9K | |
| 78264 | <1% | 41 | $9K | |
| 87205 | <1% | 2,407 | $9K | |
| 85007 | <1% | 2,882 | $9K | |
| 86900 | <1% | 3,319 | $9K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 99 | $8K |
| 27096 | <1% | 26 | $8K | |
| 43248 | <1% | 41 | $8K | |
| J2704 | Injection, propofol, 10 mg | <1% | 944 | $8K |
| 73080 | <1% | 137 | $8K | |
| 85652 | <1% | 2,518 | $7K | |
| 83921 | <1% | 430 | $7K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 186 | $7K |
| 77062 | <1% | 280 | $7K | |
| 43235 | <1% | 15 | $7K | |
| 84550 | <1% | 1,447 | $7K | |
| 86703 | <1% | 403 | $6K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 18 | $6K |
| 80076 | <1% | 830 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,177 | $6K |
| 85045 | <1% | 1,607 | $6K | |
| 87430 | <1% | 464 | $6K | |
| 87493 | <1% | 404 | $6K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 41 | $5K |
| 95819 | <1% | 26 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 225 | $5K |
| 72131 | <1% | 16 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 721 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,245 | $4K |
| 87522 | Neg quan hep c or qual rna | <1% | 137 | $4K |
| 97164 | <1% | 114 | $4K | |
| 81003 | <1% | 1,841 | $4K | |
| 87899 | <1% | 334 | $4K | |
| 84403 | <1% | 136 | $4K | |
| 97802 | <1% | 235 | $3K | |
| 97014 | <1% | 102 | $3K | |
| 84100 | <1% | 826 | $3K | |
| 93880 | <1% | 32 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 12 | $3K |
| 82570 | <1% | 656 | $3K | |
| 83516 | <1% | 214 | $3K | |
| 87046 | <1% | 178 | $3K | |
| 82043 | <1% | 672 | $3K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 336 | $3K |
| 77061 | <1% | 118 | $2K | |
| 82553 | <1% | 276 | $2K | |
| A9510 | Technetium tc-99m disofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 28 | $2K |
| 82150 | <1% | 346 | $2K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 631 | $2K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 23 | $2K |
| 74022 | <1% | 28 | $2K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 46 | $2K |
| 86706 | <1% | 251 | $2K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 26 | $2K |
| 97010 | <1% | 67 | $2K | |
| 87045 | <1% | 174 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 25 | $2K |
| 86364 | <1% | 150 | $2K | |
| 76870 | <1% | 14 | $2K | |
| 80050 | General health panel | <1% | 187 | $1K |
| 93975 | <1% | 14 | $1K | |
| 99406 | <1% | 114 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 190 | $1K |
| 72072 | <1% | 14 | $1K | |
| 86258 | <1% | 72 | $1K | |
| 85576 | <1% | 31 | $1K | |
| 86431 | <1% | 177 | $1K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 29 | $1K |
| 87147 | <1% | 148 | $1K | |
| 86334 | <1% | 59 | $1K | |
| 95886 | <1% | 21 | $978.30 | |
| 83521 | <1% | 56 | $926.17 | |
| 97163 | <1% | 12 | $903.13 | |
| 96523 | <1% | 40 | $877.21 | |
| 29125 | <1% | 16 | $851.65 | |
| 73140 | <1% | 14 | $828.60 | |
| 87641 | <1% | 36 | $767.23 | |
| 72040 | <1% | 16 | $754.82 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 100 | $726.46 |
| 80069 | <1% | 131 | $704.32 | |
| 87328 | <1% | 60 | $702.50 | |
| 36416 | <1% | 119 | $623.67 | |
| 87329 | <1% | 47 | $576.57 | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 19 | $575.70 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 88 | $556.82 |
| 82010 | <1% | 71 | $549.98 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 95 | $538.28 |
| 51701 | <1% | 25 | $513.09 | |
| 86231 | <1% | 59 | $511.38 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 17 | $501.82 |
| 84165 | <1% | 59 | $499.38 | |
| 88173 | <1% | 14 | $475.74 | |
| 83993 | <1% | 36 | $466.81 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 117 | $432.44 |
| 84480 | <1% | 52 | $422.65 | |
| 87210 | <1% | 105 | $405.47 | |
| 11721 | <1% | 88 | $379.05 | |
| 85014 | <1% | 245 | $364.29 | |
| 84207 | <1% | 14 | $358.27 | |
| 83525 | <1% | 25 | $322.98 | |
| 86376 | <1% | 15 | $299.75 | |
| 83883 | <1% | 36 | $294.21 | |
| 87340 | <1% | 52 | $280.56 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 67 | $276.17 |
| 82652 | <1% | 14 | $269.50 | |
| 90686 | <1% | 24 | $264.98 | |
| 82542 | <1% | 12 | $253.15 | |
| 85018 | <1% | 137 | $225.85 | |
| 87625 | <1% | 12 | $211.09 | |
| 82248 | <1% | 48 | $202.63 | |
| 82533 | <1% | 16 | $193.98 | |
| 84425 | <1% | 14 | $181.50 | |
| 86592 | <1% | 43 | $172.23 | |
| 86308 | <1% | 27 | $166.85 | |
| 86803 | <1% | 12 | $166.43 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 23 | $153.67 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 77 | $144.45 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 22 | $142.33 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13 | $136.01 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 14 | $133.96 |
| A4663 | Blood pressure cuff only | <1% | 68 | $121.25 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 17 | $116.18 |
| 84132 | <1% | 31 | $113.84 | |
| A9270 | Non-covered item or service | <1% | 56 | $85.99 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 17 | $75.27 |
| 87075 | <1% | 18 | $74.33 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 52 | $72.27 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 13 | $56.59 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 15 | $47.61 |
| J9055 | Injection, cetuximab, 10 mg | <1% | 17 | $36.90 |
| 84156 | <1% | 13 | $32.09 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 27 | $0.02 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSNAPP, WILLIAM (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.